Outcome

This study demonstrates that 1.6 ATA hyperbaric oxygen therapy (HBOT) is significantly more effective than 2.2 ATA HBOT in improving neurological function and reducing secondary brain injury in rats with traumatic brain injury (TBI).

Introduction

Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality worldwide with limited effective therapeutic options available. Hyperbaric oxygen therapy (HBOT) has emerged as a promising treatment modality for TBI leveraging enriched oxygen environments to enhance tissue repair and reduce inflammatory responses. However the optimal pressure settings for maximizing HBOT efficacy are still under investigation. This study aims to compare the therapeutic effects of HBOT at two different pressures 1.6 ATA and 2.2 ATA on rats with TBI. By evaluating various indicators of neural recovery and inflammation including the expression levels of extracellular histones (H1 H2A H4) and the inflammatory marker NF-κB the study seeks to determine which pressure setting offers the greatest neuroprotective benefits. The results highlight that 1.6 ATA HBOT significantly improves neurological function inhibits harmful extracellular histones and reduces nerve cell apoptosis particularly within the first six hours post-injury. These findings propose that a lower pressure HBOT protocol may provide substantial therapeutic advantages in the early treatment of TBI potentially guiding future clinical applications.

Results

The study investigated the efficacy of hyperbaric oxygen therapy (HBOT) at pressures of 1.6 ATA and 2.2 ATA on rats with traumatic brain injury (TBI) focusing on neurological recovery expression of extracellular histones and inflammatory response. Over 20 HBOT sessions conducted across 20 days the findings illustrate that the lower pressure of 1.6 ATA exhibited superior results in various metrics of recovery and healing.

Significantly 1.6 ATA HBOT markedly improved neurological function as shown by better modified Neurological Severity Scores (mNSS) in the early stages post-injury. This improvement was directly correlated with the observed decrease in the expression levels of extracellular histones (H1 H2A H4) and the inflammatory marker NF-κB around the brain lesion sites especially within the first six hours following the injury.

Moreover 1.6 ATA HBOT significantly mitigated nerve cell apoptosis. This was evidenced by lower rates of NF-κB-positive staining indicating a robust anti-inflammatory and neuroprotective effect compared to the 2.2 ATA pressure setting. The reduction in nerve cell death notably contributes to the prevention of secondary brain injury a common and debilitating consequence of TBI.

In summary the research findings conclusively demonstrate that HBOT at 1.6 ATA is more efficacious than at 2.2 ATA in fostering neural recovery and mitigating harmful cellular processes associated with TBI. These results underscore the potential of lower pressure HBOT as an optimized therapeutic approach particularly when administered promptly after brain injury by alleviating inflammation and inhibiting neurodegenerative factors. This study thereby provides a compelling case for revising HBOT protocols to maximize therapeutic outcomes for TBI patients emphasizing the critical importance of both the treatment pressure and its timing.

Conclusion

In conclusion this study underscores the efficacy of hyperbaric oxygen therapy (HBOT) at 1.6 ATA in the treatment of traumatic brain injury (TBI). The comparison between 1.6 ATA and 2.2 ATA pressures reveals that 1.6 ATA HBOT not only significantly improves neurological function but also effectively reduces the expression of damaging extracellular histones (H1 H2A H4) and the inflammatory marker NF-κB especially within the crucial initial six hours post-injury. Importantly this lower pressure therapy decreases nerve cell apoptosis thereby mitigating secondary brain injury. These findings highlight the potential of 1.6 ATA HBOT as a superior treatment protocol emphasizing its role in alleviating inflammation and cell death early after TBI. Future research should focus on further optimizing HBOT pressure settings and exploring the precise timing of the intervention to maximize therapeutic benefits for TBI patients.